Non-Hodgkin lymphoma, pediatric

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Noyd.png
David Noyd, MD, MPH
University of Oklahoma
Oklahoma City, OK

This page contains studies that were specific to pediatric populations, who are generally treated based on risk-stratification, not on the underlying histology. See individual trials for inclusion criteria.

3 regimens on this page
3 variants on this page


Untreated, pre-phase

CVP

CVP: Cyclophosphamide, Vincristine, Prednisone
COP: Cyclophosphamide, Oncovin (Vincristine), Prednisone

Regimen

Study Years of enrollment Evidence
Patte et al. 2007 (FAB/LMB96) 1996-2001 Non-randomized portion of phase 3 RCT

Chemotherapy

Glucocorticoid therapy

CNS prophylaxis

7-day course

Subsequent treatment

References

  1. FAB/LMB96: Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007 Apr 1;109(7):2773-80. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00002757

Untreated, induction

COPADM

COPADM: Cyclophosphamide, Oncovin (Vincristine), Prednisone, ADriamycin (Doxorubicin), Methotrexate

Protocol

Study Years of enrollment Evidence Comparator Comparative Efficacy
Patte et al. 2007 (FAB/LMB96) 1996-2001 Non-randomized portion of phase 3 RCT
Minard-Colin et al. 2020 (Inter-B-NHL Ritux 2010) 2011-2015 Phase 3 (C) R-COPADM Inferior OS

Note: It is not clear from Patte et al. 2007 whether the cyclophosphamide was fractionated.

Preceding treatment

Chemotherapy

Glucocorticoid therapy

Supportive medications

CNS prophylaxis

One course

Subsequent treatment

  • COPADM re-induction; reduced-dose versus COPADM re-induction; standard-dose

References

  1. FAB/LMB96: Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007 Apr 1;109(7):2773-80. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00002757
  2. Inter-B-NHL Ritux 2010: Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma; Children’s Oncology Group. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020 Jun 4;382(23):2207-2219. link to original article link to PMC article PubMed NCT01516580

R-COPADM

R-COPADM: Rituximab, Cyclophosphamide, Oncovin (Vincristine), Prednisone, ADriamycin (Doxorubicin), Methotrexate

Protocol

Study Years of enrollment Evidence Comparator Comparative Efficacy
Minard-Colin et al. 2020 (Inter-B-NHL Ritux 2010) 2011-2015 Phase 3 (E-RT-esc) COPADM Superior OS
OS36: 95.1% vs 87.3%
(HR 0.36, 95% CI 0.16-0.82)

Note: Only partial dosing information is available in the manuscript/supplement; dosing here is primarily based on FAB/LMB96.

Preceding treatment

Targeted therapy

Chemotherapy

Glucocorticoid therapy

Supportive medications

CNS prophylaxis

One course

Subsequent treatment

References

  1. Inter-B-NHL Ritux 2010: Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma; Children’s Oncology Group. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020 Jun 4;382(23):2207-2219. link to original article link to PMC article contains partial protocol PubMed NCT01516580